Compare EMR & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMR | VRTX |
|---|---|---|
| Founded | 1890 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | EDP Services |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.6B | 115.7B |
| IPO Year | 1994 | 2006 |
| Metric | EMR | VRTX |
|---|---|---|
| Price | $139.21 | $490.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 28 |
| Target Price | $157.85 | ★ $536.24 |
| AVG Volume (30 Days) | ★ 3.2M | 1.3M |
| Earning Date | 05-04-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.58% | N/A |
| EPS Growth | 17.78 | ★ 836.54 |
| EPS | 1.07 | ★ 15.32 |
| Revenue | ★ $24,412,000,000.00 | $2,488,652,000.00 |
| Revenue This Year | $6.26 | $10.79 |
| Revenue Next Year | $5.44 | $10.14 |
| P/E Ratio | $131.50 | ★ $32.63 |
| Revenue Growth | 0.78 | ★ 46.20 |
| 52 Week Low | $90.06 | $362.50 |
| 52 Week High | $165.15 | $519.68 |
| Indicator | EMR | VRTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.30 | 54.64 |
| Support Level | $127.05 | $428.47 |
| Resistance Level | $150.27 | $503.88 |
| Average True Range (ATR) | 4.23 | 15.98 |
| MACD | -1.41 | 1.00 |
| Stochastic Oscillator | 24.13 | 66.35 |
Founded in 1890 as the first manufacturer of electric fans in North America, Emerson Electric has become a leading industrial automation player through the acquisition of established brands. Emerson organizes its business into seven segments that sell a wide range of automation software, power tools, and automation hardware such as valves, gauges, and switches. In recent years, Emerson divested its climate technology and consumer businesses to become more of a pure-play industrial automation company. The automation of a factory is an enticing long-term proposition for manufacturers, helping reduce accident rates and raise uptime and productivity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.